Stock 600538 BEIHAI GOFAR CHUANSHAN BIOLOGICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Beihai Gofar Chuanshan Biological Co., Ltd.

Equities

600538

CNE000001DD2

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
4.14 CNY -6.33% Intraday chart for Beihai Gofar Chuanshan Biological Co., Ltd. -11.73% -10.78%
Apr. 29 Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 22 Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,997 2,350 3,019 3,166 2,369 2,432
Enterprise Value (EV) 1 1,703 2,118 2,792 2,982 2,213 2,293
P/E ratio -86 x 407 x 843 x 302 x 64.6 x -29 x
Yield - - - - - -
Capitalization / Revenue 9.09 x 9.36 x 11.3 x 7.45 x 5.15 x 6.59 x
EV / Revenue 7.75 x 8.43 x 10.4 x 7.02 x 4.81 x 6.21 x
EV / EBITDA -556 x 2,432 x 209 x 133 x 60 x -293 x
EV / FCF -43.4 x -144 x 38.7 x -30.2 x -137 x -389 x
FCF Yield -2.3% -0.69% 2.58% -3.31% -0.73% -0.26%
Price to Book 3.13 x 3.64 x 3.58 x 3.45 x 2.49 x 2.8 x
Nbr of stocks (in thousands) 464,401 464,401 511,771 524,198 524,198 524,198
Reference price 2 4.300 5.060 5.900 6.040 4.520 4.640
Announcement Date 4/23/19 4/20/20 4/26/21 3/28/22 4/17/23 4/22/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 219.6 251.2 267.7 424.7 459.7 369.2
EBITDA 1 -3.06 0.8706 13.39 22.44 36.86 -7.837
EBIT 1 -16.73 -14.55 2.008 9.418 24.1 -21.46
Operating Margin -7.62% -5.79% 0.75% 2.22% 5.24% -5.81%
Earnings before Tax (EBT) 1 -9.834 10.41 9.572 15.79 42.11 -77.57
Net income 1 -21.61 5.773 3.201 10.49 34.86 -82.31
Net margin -9.84% 2.3% 1.2% 2.47% 7.58% -22.3%
EPS 2 -0.0500 0.0124 0.007000 0.0200 0.0700 -0.1600
Free Cash Flow 1 -39.22 -14.72 72.06 -98.63 -16.19 -5.894
FCF margin -17.86% -5.86% 26.92% -23.22% -3.52% -1.6%
FCF Conversion (EBITDA) - - 538.31% - - -
FCF Conversion (Net income) - - 2,251.41% - - -
Dividend per Share - - - - - -
Announcement Date 4/23/19 4/20/20 4/26/21 3/28/22 4/17/23 4/22/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 294 232 227 184 156 139
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -39.2 -14.7 72.1 -98.6 -16.2 -5.89
ROE (net income / shareholders' equity) -1.59% 0.9% 0.43% 1.12% 3.9% -8.83%
ROA (Net income/ Total Assets) -1.36% -1.2% 0.14% 0.55% 1.35% -1.22%
Assets 1 1,592 -480.4 2,319 1,914 2,575 6,744
Book Value Per Share 2 1.370 1.390 1.650 1.750 1.820 1.660
Cash Flow per Share 2 0.2500 0.5000 0.4100 0.3600 0.3300 0.3000
Capex 1 26.4 4.5 1.39 23.3 7.77 10
Capex / Sales 12.03% 1.79% 0.52% 5.48% 1.69% 2.72%
Announcement Date 4/23/19 4/20/20 4/26/21 3/28/22 4/17/23 4/22/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
BEIHAI GOFAR CHUANSHAN BIOLOGICAL CO., LTD. Stock Beihai Gofar Chuanshan Biological Co., Ltd.
-10.78% 300M
MCKESSON CORPORATION Stock McKesson Corporation
+26.60% 76.19B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-1.98% 24.06B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+10.27% 8.83B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+10.22% 8.51B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-22.96% 7.72B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+12.58% 5.2B
GALENICA AG Stock Galenica AG
+3.02% 4.18B
EBOS GROUP LIMITED Stock EBOS Group Limited
-5.61% 4.01B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+4.85% 3.86B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 600538 Stock
  4. Financials Beihai Gofar Chuanshan Biological Co., Ltd.